13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
28 檔
24.0%
According to the latest 13F quarterly dataset, Acuta Capital Partners, LLC managed an equity portfolio of $143.5M at the end of Q2 2025, spanning 28 distinct U.S. exchange-listed positions.
In Q2 2025, Acuta Capital Partners, LLC adopted a defensive or profit-taking posture, trimming 13 positions and completely liquidating 10 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 13.15% | +0.07% | -16.79% | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 12.21% | — | +42.85% | |
| 3 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 8.90% | +6.59% | — | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.42% | — | -5.51% | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 6.33% | — | -33.55% | |
| 6 | ASND | Ascendis Pharma A/S | Stock-Other | 5.44% | — | -3.27% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 5.21% | — | -65.05% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.16% | +0.60% | -4.57% | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.35% | -0.13% | -14.98% | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.89% | — | +174.50% | |
| 11 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.77% | — | -37.18% | |
| 12 | OCS | Oculis Holding AG | Stock-Other | 2.89% | -1.86% | EXIT | |
| 13 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.86% | -1.80% | EXIT | |
| 14 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.78% | — | — | |
| 15 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.42% | -18.59% | EXIT | |
| 16 | SRZN | Surrozen Inc | Stock-Other | 2.12% | -0.44% | — | |
| 17 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.77% | -1.27% | -18.87% | |
| 18 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.57% | +1.27% | — | |
| 19 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.47% | — | — | |
| 20 | ZYME | Zymeworks Inc | Stock-Other | 1.47% | — | +22.20% | |
| 21 | LQDA | Liquidia CORP | Stock-Other | 1.32% | — | -50.56% | |
| 22 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.21% | — | +11.86% | |
| 23 | VSTM | Verastem Inc | Stock-Other | 0.87% | — | -14.54% | |
| 24 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.57% | — | — | |
| 25 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.42% | -0.27% | EXIT | |
| 26 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.32% | — | +21.95% | |
| 27 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.10% | +1.76% | NEW | |
| 28 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +9.1% | +42.85% | Add |
| 2 | OCUL | Ocular Therapeutix Inc | +2.8% | -16.79% | Trim |
| 3 | JAZZ | Jazz Pharmaceuticals plc | +2.5% | +174.50% | Add |
| 4 | SLNOEUR | Soleno Therapeutics Inc | +1.9% | -5.51% | Trim |
| 5 | WHWK | Whitehawk Therapeutics Inc | +1.9% | — | Unchanged |
| 6 | TSHA | Taysha Gene Therapies Inc | +1.6% | NEW | New buy |
| 7 | AKRO | Akero Therapeutics Inc | +1.5% | NEW | New buy |
| 8 | 430 | Terns Pharmaceuticals Inc | +1.4% | +42.49% | Add |
| 9 | ASND | Ascendis Pharma A/S | +1.2% | -3.27% | Trim |
| 10 | FULC | Fulcrum Therapeutics Inc | +0.6% | NEW | New buy |
| 11 | ZYME | Zymeworks Inc | +0.5% | +22.20% | Add |
| 12 | PRAX | Praxis Precision Medicines I | +0.5% | -14.98% | Trim |
| 13 | UNCY | Unicycive Therapeutics Inc | +0.4% | NEW | New buy |
| 14 | ARGX | Argenx Se - Adr | +0.3% | -4.57% | Trim |
| 15 | ✓ | Helix Acquisition CORP Ii | +0.3% | — | Unchanged |
| 16 | RARE | Ultragenyx Pharmaceutical In | +0.3% | +11.86% | Add |
| 17 | RVMD | Revolution Medicines Inc | +0.1% | -16.45% | Trim |
| 18 | OCS | Oculis Holding AG | +0.1% | -14.63% | Trim |
| 19 | RAPP | Rapport Therapeutics Inc | +0.1% | +21.95% | Add |
| 20 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 21 | ✓ | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 22 | ARTV | Artiva Biotherapeutics Inc | -0.1% | — | Unchanged |
| 23 | FBRX | Forte Biosciences Inc | -0.2% | EXIT | Sold out |
| 24 | SRZN | Surrozen Inc | -0.2% | — | Unchanged |
| 25 | VSTM | Verastem Inc | -0.4% | -14.54% | Trim |
| 26 | RCKT | Rocket Pharmaceuticals Inc | -0.6% | EXIT | Sold out |
| 27 | DRUG | Bright Minds Biosciences Inc | -0.7% | -18.87% | Trim |
| 28 | ✓ | Verve Therapeutics Inc | -0.9% | EXIT | Sold out |
| 29 | TRML | Tourmaline Bio Inc | -1.2% | -33.55% | Trim |
| 30 | GILD | Gilead Sciences Inc | -1.2% | EXIT | Sold out |
| 31 | LQDA | Liquidia CORP | -1.3% | -50.56% | Trim |
| 32 | ✓ | -1.6% | EXIT | Sold out | |
| 33 | TRVI | Trevi Therapeutics Inc | -2% | -37.18% | Trim |
| 34 | MREO | Mereo Biopharma Group Pl-adr | -2.1% | EXIT | Sold out |
| 35 | EWTX | Edgewise Therapeutics Inc | -2.2% | EXIT | Sold out |
| 36 | MRK | Merck & Co. Inc. | -2.4% | EXIT | Sold out |
| 37 | INSM | Insmed Inc | -4.2% | -65.05% | Trim |
| 38 | ELVN | Enliven Therapeutics Inc | -6.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 28 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, CDTX, WHWK) accounted for 24.0% of total reported equity market value during Q2 2025.
Top New Position Initiated
TSHA
市值: $1.1M
Top Position Liquidated / Trimmed
ELVN
前期市值: $5.2M
During Q2 2025, Acuta Capital Partners, LLC's top holdings by market value included OCUL (13.2%)、CDTX (12.2%)、WHWK (8.9%). The largest single position, OCUL, represented 13.2% of total portfolio value.
In Q2 2025, Acuta Capital Partners, LLC made 33 total portfolio adjustments, initiating 4 new buys, adding to 6 positions, trimming 13 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.